Telangiectasia, hereditary hemorrhagic, type 1
MONDO:0008535Also known as: HHT1, hereditary hemorrhagic telangiectasia type 1, telangiectasia, hereditary hemorrhagic, of Rendu, Osler, and Weber, telangiectasia, hereditary hemorrhagic, type 1, ENG-related Hereditary hemorrhagic telangiectasia, HHT, ORW disease, Osler Weber Rendu syndrome type 1
9 clinical trials for this condition and its sub-types, 4 tagged with Telangiectasia, hereditary hemorrhagic, type 1 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Could a cancer pill stop debilitating nosebleeds? new trial hopes so.
Disease control OngoingThis study tests whether a low dose of pazopanib, a drug currently used for cancer, can reduce severe nosebleeds and improve anemia in people with hereditary hemorrhagic telangiectasia (HHT). About 70 participants will take either the drug or a placebo daily for 24 weeks. Researc…
Phase 2/3 • Sponsor: Cure HHT • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New registry aims to unlock secrets of rare bleeding disorder
Knowledge-focused OngoingThis study is creating a registry of people with Hereditary Hemorrhagic Telangiectasia (HHT), a rare condition that causes abnormal blood vessels and frequent nosebleeds. Researchers will collect health information from about 1,000 adults over many years to see how the disease ch…
Sponsor: Unity Health Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New registry monitors VBX stent graft in Real-World use
Knowledge-focused OngoingThis study is a registry that collects safety and performance data on the GORE® VIABAHN® VBX Stent Graft when used in peripheral vessels. It involves 280 adults who need this device to treat peripheral vascular disease. The goal is to see how well the stent graft works and if the…
Sponsor: W.L.Gore & Associates • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC